Alzamend Neuro (NASDAQ: ALZN) announced the first patient has been dosed in its Phase II clinical trial of AL001, a novel lithiu ...

The COMMANDS study (NCT03682536) - a phase 3 open-label, randomised trial to ... frequent transfusions are associated with an increased risk of iron overload, transfusion reactions, and infections ...

LAWRENCEVILLE, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the U ...

SAN DIEGO, April 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 3 registrational program to evaluate the efficacy, safety and ...

Findings showed statistically significant reductions in the ADHD Investigator Symptom Report Scale total score were seen with solriamfetol 150mg vs placebo at week 6. Topline data were announced ...